

Atorvastatin treatment in Systemic Lupus Erythematosus patients

Submission date 19/01/2011	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 18/02/2011	Overall study status Completed	☐ Statistical analysis plan
		☐ Results
Last Edited 18/02/2011	Condition category Musculoskeletal Diseases	☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Wojciech Plazak

Contact details

Pradnicka Str 80

Krakow

Poland

31-202

+48 (0)604 90 33 99

wplazak@szpitaljp2.krakow.pl

Additional identifiers

Protocol serial number

N40201231/0460

Study information

Scientific Title

Influence of Atorvastatin on coronary calcifications and myocardial perfusion defects in Systemic Lupus Erythematosus patients: a prospective, randomised, double-masked, placebo-controlled study

Acronym

Atorvastatin-SLE

Study objectives

This study was conducted to determine the effect of atorvastatin treatment on multidetector computed tomography (MDCT)-based coronary calcium scoring and single photon emission computed tomography (SPECT)-assessed myocardial perfusion abnormalities in systemic lupus erythematosus (SLE) patients free of cardiovascular disease clinical symptoms.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethical Committee of the Jagiellonian University in Krakow, Poland, approved on the 12th January 2006 (ref: KBET/2/L/2006)

Study design

Prospective randomised double-masked placebo-controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Systemic lupus erythematosus

Interventions

Atorvastatin treatment (40 mg/day) versus placebo. Total duration of treatment: 1 year. One year follow-up period.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Atorvastatin

Primary outcome(s)

Measured at 0 and 12 months:

1. Calcium deposits in coronary arteries
2. Number of myocardial left ventricle segments with perfusion defects

Key secondary outcome(s))

Measured at 0, 3, 6, 12 months:

1. Symptoms of myocardial ischaemia
2. Need for reperfusion therapy
3. Deaths

Completion date

10/11/2010

Eligibility

Key inclusion criteria

1. Patients aged 20 - 73, either sex
2. Fulfilled at least 4 American College of Rheumatology (ACR) classification criteria for SLE
3. In stable clinical conditions (no need for immunosuppressive therapy intensification, i.e. current immunosuppressive drug dose increase or introduction of an additional immunosuppressive drug within last 3 months)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Known cancer
2. Clinical symptoms of coronary heart disease or heart failure (New York Heart Association [NYHA] III or IV class)
3. Renal failure (creatinine clearance less than 30 ml/min)
4. Respiratory failure

Date of first enrolment

01/01/2006

Date of final enrolment

10/11/2010

Locations

Countries of recruitment

Poland

Study participating centre
Pradnicka Str 80
Krakow
Poland
31-202

Sponsor information

Organisation
Polish Ministry of Science and Higher Education (Poland)

ROR
<https://ror.org/05dwvd537>

Funder(s)

Funder type
Government

Funder Name
Polish Ministry of Science and Higher Education (Poland) (ref: N40201231/0460)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration